Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH
2007-004865-17Phase 3Terminated
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- Aug 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Cetrorelix pamoate in benign prostatic hyperplasia (BPH), sponsored by COSCIENS Biopharma Inc. Primary endpoint: Incidence of treatment-emergent adverse events. Started Aug 2008; status: terminated.
02
Drugs
Cetrorelix pamoate
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2007-004865-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004865-17.